Piperlongumine inhibits proliferation and oncogenic MYCN expression in chemoresistant metastatic retinoblastoma cells directly and through extracellular vesicles

Piperlongumine inhibits proliferation and oncogenic MYCN expression in chemoresistant metastatic retinoblastoma cells directly and through extracellular vesicles

Ocular retinoblastoma malignancies, which develop into metastatic phenotypes, result in poor prognosis and survival for infant and child patients. To improve the prognosis of metastatic retinoblastoma, it is important to identify novel compounds with less toxic side effects and higher therapeutic ef...

Full description

Bibliographic Details
Main Authors:	Cui Shi, Kunhui Huang, John Soto, Renuka Sankaran, Vrinda Kalia, Onyekwere Onwumere, Michael Young, Linda Einbond, Stephen Redenti
Format:	Article
Language:	English
Published:	Elsevier 2023-05-01
Series:	Biomedicine & Pharmacotherapy
Subjects:	Metastatic retinoblastoma Piperlongumine Extracellular vesicles Chemotherapeutic drugs Chemoresistance MYCN
Online Access:	http://www.sciencedirect.com/science/article/pii/S0753332223003426

Similar Items

Early Mechanisms of Chemoresistance in Retinoblastoma
by: Michelle G. Zhang, et al.
Published: (2022-10-01)

High-Level MYCN-Amplified RB1-Proficient Retinoblastoma Tumors Retain Distinct Molecular Signatures
by: Khashayar Roohollahi, MSc, et al.
Published: (2022-09-01)

The Oncogene <i>MYCN</i> Modulates Glycolytic and Invasive Genes to Enhance Cell Viability and Migration in Human Retinoblastoma
by: Swatishree Sradhanjali, et al.
Published: (2021-10-01)

Clinical, Genomic, and Pharmacological Study of <em>MYCN</em>-Amplified <em>RB1</em> Wild-Type Metastatic Retinoblastoma
by: Santiago Zugbi, et al.
Published: (2020-09-01)

Ceftriaxone exerts antitumor effects in MYCN‐driven retinoblastoma and neuroblastoma by targeting DDX3X for translation repression
by: Pamorn Chittavanich, et al.
Published: (2024-04-01)

Piperlongumine as a Neuro-Protectant in Chemotherapy Induced Cognitive Impairment
by: Fabio Ntagwabira, et al.
Published: (2022-02-01)

Antimicrobial and Synergistic Effects of Commercial Piperine and Piperlongumine in Combination with Conventional Antimicrobials
by: Eunice Ego Mgbeahuruike, et al.
Published: (2019-05-01)

Reciprocal Induction of MDM2 and MYCN in Neural and Neuroendocrine Cancers
by: Hung N. Tran, et al.
Published: (2020-12-01)

Piperlongumine-Induced Phosphatidylserine Translocation in the Erythrocyte Membrane
by: Rosi Bissinger, et al.
Published: (2014-10-01)

Identification of Piperlongumine as Potent Inhibitor of Necroptosis
by: He X, et al.
Published: (2023-05-01)

Overcoming tumor cell chemoresistance using nanoparticles: lysosomes are beneficial for (stearoyl) gemcitabine-incorporated solid lipid nanoparticles
by: Chen Z, et al.
Published: (2018-01-01)

Synthesis and Spectroscopic Analysis of Piperine- and Piperlongumine-Inspired Natural Product Scaffolds and Their Molecular Docking with IL-1β and NF-κB Proteins
by: Gabriel Zazeri, et al.
Published: (2020-06-01)

Piperlongumine Is an NLRP3 Inhibitor With Anti-inflammatory Activity
by: Jie Shi, et al.
Published: (2022-01-01)

Piperlongumine alleviates corneal allograft rejection via suppressing angiogenesis and inflammation
by: Xiangyu Fan, et al.
Published: (2022-12-01)

Piperlongumine activates Sirtuin1 and improves cognitive function in a murine model of Alzheimer’s disease
by: Jun Go, et al.
Published: (2018-04-01)

The Synergistic Effect of Piperlongumine and Sanguinarine on the Non-Small Lung Cancer
by: Marta Hałas-Wiśniewska, et al.
Published: (2020-07-01)

Potential Role of miRNAs in the Acquisition of Chemoresistance in Neuroblastoma
by: Barbara Marengo, et al.
Published: (2021-02-01)

Metastatic retinoblastoma at presentation: Clinical presentation, treatment, and outcomes
by: Chandra L Kakarala, et al.
Published: (2023-01-01)

New retinoblastoma (RB) drug delivery approaches: anti‐tumor effect of atrial natriuretic peptide (ANP)‐conjugated hyaluronic‐acid‐coated gold nanoparticles for intraocular treatment of chemoresistant RB
by: André Haase, et al.
Published: (2024-04-01)

The promising potential of piperlongumine as an emerging therapeutics for cancer
by: Dey Parama, et al.
Published: (2021-08-01)

Epigenetic Dysregulation in <i>MYCN</i>-Amplified Neuroblastoma
by: Soraya Epp, et al.
Published: (2023-12-01)

Piperlongumine Induces Cellular Apoptosis and Autophagy via the ROS/Akt Signaling Pathway in Human Follicular Thyroid Cancer Cells
by: Tsung-Hsing Lin, et al.
Published: (2023-04-01)

Piperlongumine treatment impacts heart and liver development and causes developmental delay in zebrafish (Danio rerio) embryos
by: Hwang-Ju Jeon, et al.
Published: (2023-06-01)

Piperlongumine-Eluting Gastrointestinal Stent Using Reactive Oxygen Species-Sensitive Nanofiber Mats for Inhibition of Cholangiocarcinoma Cells
by: Hyung Ha Jang, et al.
Published: (2019-02-01)

On the Inhibition Mechanism of Glutathione Transferase P1 by Piperlongumine. Insight From Theory
by: Mario Prejanò, et al.
Published: (2018-12-01)

Piperlongumine Inhibits Thioredoxin Reductase 1 by Targeting Selenocysteine Residues and Sensitizes Cancer Cells to Erastin
by: Yijia Yang, et al.
Published: (2022-04-01)

Inhibitors of the Oncogenic PA2G4-MYCN Protein-Protein Interface
by: Hassina Massudi, et al.
Published: (2023-03-01)

Piperlongumine is a ligand for the orphan nuclear receptor 4A1 (NR4A1)
by: Lei Zhang, et al.
Published: (2023-09-01)

Piperlongumine Attenuates High Calcium/Phosphate-Induced Arterial Calcification by Preserving P53/PTEN Signaling
by: Wenxiang Shi, et al.
Published: (2021-02-01)

Metastasis in neuroblastoma: the MYCN question
by: Swapnil Parashram Bhavsar
Published: (2023-05-01)

Targeting MYCN in paediatric cancers
by: Arturo eSala
Published: (2015-05-01)

Preventive potentials of piperlongumine and a Piper longum extract against stress responses and pain
by: Vaishali Yadav, et al.
Published: (2016-10-01)

MYCN Amplification Is Associated with Reduced Expression of Genes Encoding γ-Secretase Complex and NOTCH Signaling Components in Neuroblastoma
by: Prasoon Agarwal, et al.
Published: (2023-05-01)

SMAD9-MYCN positive feedback loop represents a unique dependency for MYCN-amplified neuroblastoma
by: Kezhe Tan, et al.
Published: (2022-12-01)

Piperlongumine Inhibits Titanium Particles-Induced Osteolysis, Osteoclast Formation, and RANKL-Induced Signaling Pathways
by: Xuan Liu, et al.
Published: (2022-03-01)

Effects of novel pyrrolomycin MP1 in MYCN amplified chemoresistant neuroblastoma cell lines alone and combined with temsirolimus
by: Timothy R. McGuire, et al.
Published: (2019-08-01)

Piperlongumine Analogs Promote A549 Cell Apoptosis through Enhancing ROS Generation
by: Ai-Ling Sun, et al.
Published: (2021-05-01)

Retinoblastoma
by: Francois Doz, et al.
Published: (2019-09-01)

Piperlongumine Induces Apoptosis and Cytoprotective Autophagy via the MAPK Signaling Pathway in Human Oral Cancer Cells
by: Eun-Young Choi, et al.
Published: (2023-09-01)

MYCN and the Epigenome
by: Stanley eHe, et al.
Published: (2013-01-01)